
Strata Critical Medical, Inc.: updates and filings
Price
$4.96
November 18, 2026Market cap $431M
What Ploutos Investor adds for Strata Critical Medical
Part of Ploutos Investor, €9.99 a month
- The full history: 7 fiscal years, from FY2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 3, 2026next Feb 4, 2027
A rough estimate from when it has reported before, which has varied. The company announces the date itself.
November 2026
August 2026
May 2026
March 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 3, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 3, 2026Results of operationsForm8-K
- Oct 15, 2026Over-5% holder statement (active)FormSCHEDULE 13D
- Aug 20, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 4, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 4, 2026Results of operationsForm8-K
- Jul 8, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 17, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 3, 2026Shareholder voteForm8-K
- May 8, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- May 6, 2026One of its securities removed from an exchange (usually a matured note)Form25-NSE
- May 6, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 6, 2026Results of operationsForm8-K
- Apr 30, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 16, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Apr 14, 2026Additional annual meeting materialFormDEFA14A
- Apr 14, 2026Annual meeting proxy statementFormDEF 14A
- Apr 8, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Apr 7, 2026Over-5% holder statement (active)FormSCHEDULE 13D
- Mar 3, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 3, 2026Results of operationsForm8-K
- Feb 5, 2026Material agreement entered, Regulation FD disclosureForm8-K
- Jan 21, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Dec 3, 2025Officer or director change, Regulation FD disclosureForm8-K
- Dec 2, 2025Acquisition or disposal of assets (amendment)Form8-K/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 3, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 3, 2026 | 8-K | Results of operations | Document |
| Oct 15, 2026 | SCHEDULE 13D | Over-5% holder statement (active) | Document |
| Aug 20, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 4, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 4, 2026 | 8-K | Results of operations | Document |
| Jul 8, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 17, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 3, 2026 | 8-K | Shareholder vote | Document |
| May 8, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| May 6, 2026 | 25-NSE | One of its securities removed from an exchange (usually a matured note) | Document |
| May 6, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 6, 2026 | 8-K | Results of operations | Document |
| Apr 30, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 16, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Apr 14, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 14, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 8, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Apr 7, 2026 | SCHEDULE 13D | Over-5% holder statement (active) | Document |
| Mar 3, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 3, 2026 | 8-K | Results of operations | Document |
| Feb 5, 2026 | 8-K | Material agreement entered, Regulation FD disclosure | Document |
| Jan 21, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Dec 3, 2025 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Dec 2, 2025 | 8-K/A | Acquisition or disposal of assets (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 26, 2019.
The full analysis
What do Strata Critical Medical's filings show?
The filings are where every one of Strata Critical Medical's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.